Pamidronat-Dinatrium Hospira (Pamidronate Disodium)

Pamidronate Disodium is indicated for conditions affecting bone turnover within the oncologic and metabolic pathways.

• Hypercalcaemia of malignancy: helps normalize elevated serum calcium levels.
• Bone metastases associated with solid tumours: reduces skeletal‑related events such as pathological fractures.
• Osteolytic lesions in multiple myeloma: diminishes bone pain and stabilises bone integrity.
• Paget’s disease of bone (when oral bisphosphonates are unsuitable): provides rapid control of abnormal bone remodeling.

• Pamidronate binds to hydroxy‑apatite crystals at sites of active bone resorption and is internalised by osteoclasts during bone remodeling. Within the osteoclast, it inhibits farnesyl pyrophosphate synthase, a key enzyme of the mevalonate pathway, disrupting prenylation of small GTP‑binding proteins and ultimately inducing osteoclast apoptosis, which reduces bone turnover.

Adverse reactions to pamidronate may vary in frequency and severity.

Common Side Effects

• Acute phase reaction: fever, myalgia, arthralgia or flu‑like symptoms.
• Nausea or vomiting.
• Transient hypocalcaemia.
• Headache.
• Injection site discomfort.

Serious or Rare Side Effects

• Renal impairment or acute kidney injury.
• Severe hypocalcaemia with tetany.
• Osteonecrosis of the jaw (ONJ).
• Atypical femoral fractures.
• Anaphylactic or severe hypersensitivity reactions.

When using pamidronate, clinicians should assess patient‑specific factors and monitor relevant parameters.

• Renal function: evaluate baseline creatinine clearance and adjust if necessary.
• Serum calcium: correct hypocalcaemia before initiation.
• Concomitant nephrotoxic drugs: avoid or use with caution.
• Dental health: obtain dental evaluation prior to therapy to reduce ONJ risk.
• Pregnancy and lactation: contraindicated unless clearly needed; discuss risks.
• Store at ambient temperature: keep in original container, protect from light and moisture.

Pamidramate may interact with several co‑administered agents, requiring clinical vigilance.

Major Interactions (Avoid)

• Concurrent high‑dose NSAIDs or aminoglycosides: increase risk of renal toxicity.
• Calcium‑containing antacids or supplements given within 4 hours of infusion: reduce drug absorption and efficacy.

Moderate Interactions (Monitor Closely)

• Loop diuretics: may potentiate hypocalcaemia.
• Vitamin D analogues: require calcium monitoring.
• Other bisphosphonates: cumulative effect on bone turnover and renal function.
• Anticoagulants (e.g., warfarin): monitor INR closely due to potential additive effects on bleeding risk.